Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study
Year: 2020
Type: article
Source: Blood
Authors: Gérard Socié, Dietger Niederwieser, Nikolas Von Bubnoff, Mohamad Mohty, Jeffrey Szer, Reuven Or, Jason P Butler, Eva Maria Wagner, Edouard Forcade, Jaime Sanz Caballer, Domenico Russo, Giovanni Grillo, Tsila Zuckerman, Sinem Civriz Bozdag, David Ritchie, Shalini Chaturvedi, Anirudh Prahallad, Karen Sinclair, Celine Wilke, Robert Zeiser
Institutions: Inserm, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Laboratoire d'hématologie, Leipzig University, University Hospital Schleswig-Holstein, Sorbonne Université, Hôpital Saint-Antoine, Centre de Recherche Saint-Antoine, The Royal Melbourne Hospital, Hadassah Medical Center, Royal Brisbane and Women's Hospital, University Medical Center of the Johannes Gutenberg University Mainz, Centre Hospitalier Universitaire de Bordeaux, Hôpital Cardiologique du Haut-Lévêque, Hospital Universitari i Politècnic La Fe, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, University of Brescia, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Rambam Health Care Campus, Ankara University, Peter MacCallum Cancer Centre, Novartis (Switzerland), University of Freiburg, University Medical Center Freiburg
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3094717363